LUMOXITI
PeakBLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
LUMOXITI by Innate Pharma is pasudotox-tdfk is a cd22-directed cytotoxin. Approved for refractory hairy cell leukemia (hcl), including treatment with a purine nucleoside analog (pna). First approved in 2018.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMOXITI (moxetumomab pasudotox-tdfk) is a CD22-directed cytotoxin conjugate approved for refractory hairy cell leukemia (HCL) in patients who have failed prior purine nucleoside analog therapy. The drug binds CD22 on B-cell surfaces, internalizes, and triggers apoptosis by inhibiting protein synthesis through ADP-ribosylation of elongation factor 2.
Peak
Product is in peak commercial phase with modest competitive pressure (30%), suggesting stable demand in a niche indication with selective commercial expansion opportunities.
Mechanism of Action
pasudotox-tdfk is a CD22-directed cytotoxin. Moxetumomab pasudotox-tdfk binds CD22 on the cell surface of B-cells and is internalized. Moxetumomab pasudotox-tdfk internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death.
Worked on LUMOXITI at Innate Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.